Bernd Seizinger, CEO of GPC Biotech, said: “We are disappointed, but we understand Celgene’s decision given their recent withdrawal of the marketing authorization application for satraplatin in Europe.
Since 2001, Lilly has utilized Phase Forward’s InForm product in over 200 trials and plans to continue to use InForm for global trials across all phases, as well
Mr Mirken will replace Jerry Swon who has been CEO and board chairman since 2001. Mr Swon will be retiring from these positions to pursue other business interests.
The trial demonstrated that the product had a good safety profile and was well tolerated and effective in lowering blood glucose levels in patients with type 2 diabetes.
RPI-78M is ReceptoPharm’s drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is its leading antiviral drug candidate. Paul Reid, CEO of ReceptoPharm, said: “This
According to the news source, GlaxoSmithKline (GSK) is proposing a new ‘price-volume’ deal to address the concerns of the National Institute for Health and Clinical Excellence (NICE), the
Under the terms of this agreement with Harvard, Oxford Nanopore has exclusive rights to develop and commercialize a number of nanopore technological breakthroughs developed in the laboratories of
The study achieved its primary endpoint. Heplisav is being jointly developed by Dynavax and Merck for use in adults and in patients with end stage renal disease. This
The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be
For the six months ended June 30, 2008, Acadia reported a net loss of $34.7 million, or $0.94 per common share, compared to a net loss of $23.3
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.